DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
03/29/2023* -- Results Q4 2022 -- -0.39 --
11/10/2022 -- Results Q3 2022 -0.40 -0.37 -7.14%
08/11/2022 -- Results Q2 2022 -0.44 -0.29 -51.72%
05/12/2022 -- Results Q1 2022 -0.38 -0.30 -25.28%
03/29/2022 -- Results Q4 2021 -0.35 -0.31 -12.90%
11/04/2021 -- Results Q3 2021 -0.39 -0.37 -6.36%
08/05/2021 -- Results Q2 2021 -0.45 -0.38 -18.37%
05/06/2021 -- Results Q1 2021 -0.29 -0.38 23.18%
*Estimated Date/Time

Earnings

Next Report Date 03/29/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/10/2022
Beat/Miss Upgrade
Return Since 2.23%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections.
URL https://www.adverum.com
Investor Relations URL https://investors.adverum.com
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Mar. 29, 2023 (est.)
Last Earnings Release Nov. 10, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio --
Cash Payout Ratio --
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Annual Total Returns Versus Peers

Loading chart...
Name
2016
2017
2018
2019
2020
2021
2022
YTD
-69.54%
20.69%
-10.00%
265.7%
-5.90%
-83.76%
-67.07%
29.06%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-18.11%
3.28%
63.37%
16.67%
-79.93%
-17.17%
8.91%
-45.97%
-85.21%
-23.59%
-23.93%
70.05%
-17.52%
10.42%
-13.60%
-24.30%
-79.98%
21.09%
-29.46%
-55.16%
-57.46%
-66.95%
321.7%
-47.71%
-96.76%
361.3%
-66.70%
-33.39%
-96.85%
-9.48%
-24.44%
-28.93%
-83.29%
38.52%
As of March 23, 2023.

Profile

Edit
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections.
URL https://www.adverum.com
Investor Relations URL https://investors.adverum.com
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Mar. 29, 2023 (est.)
Last Earnings Release Nov. 10, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter ADVM Tweets